Last updated: June 27, 2026
Sebela International Limited sued Prinston Pharmaceutical, Inc. under Hatch-Waxman-style patent infringement theories in a case docketed as 2:17-cv-04964. This is a patent litigation matter connected to pharmaceutical product exclusivity and potential generic/ANDA entry risk.
Litigation outcome, asserted patent numbers, claim constructions, settlement terms, and any final judgment are not provided in the input record. Without those case-specific facts, a complete and accurate litigation analysis cannot be produced.
What is SEBELA INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL, INC. (2:17-cv-04964) about?
Answer: A U.S. federal patent infringement case filed by Sebela International Limited against Prinston Pharmaceutical, Inc., docketed at 2:17-cv-04964 (filed in 2017). The matter concerns asserted pharmaceutical IP tied to FDA-regulated products and potential market entry by a generic applicant.
What court and parties are listed on docket 2:17-cv-04964?
- Plaintiff: Sebela International Limited
- Defendant: Prinston Pharmaceutical, Inc.
- Case number: 2:17-cv-04964
- Year filed: 2017
What type of litigation is it?
Answer: Patent infringement litigation typically tied to Paragraph IV ANDA or similar regulatory infringement frameworks, but the specific asserted regulatory filing type is not contained in the provided input.
Which patents were asserted in SEBELA v. PRINSTON (2:17-cv-04964)?
Answer: The specific patent numbers, expiration dates, and assignees asserted in this case are not provided in the input record.
What claims or patent categories are typically at issue in these disputes?
Common pharmaceutical cases in this posture involve one or more of:
- composition-of-matter patents
- formulation patents (including dissolution, polymorph, or particle-size claims)
- method-of-use patents
- manufacturing or process patents
- secondary use or therapeutic regimen patents
No asserted-patent list is available in the input, so no accurate mapping can be performed.
What did the complaint allege, and what was Prinston’s response in SEBELA v. PRINSTON?
Answer: The pleadings’ substance is not provided in the input record.
What defenses are commonly raised in these cases?
Typical defenses include:
- non-infringement
- invalidity (anticipation, obviousness, lack of enablement, indefiniteness)
- procedural defenses (jurisdiction, standing, timing, pleading sufficiency)
No case-specific defense content is available here.
How far did the case progress procedurally (motions, Markman, trial) in 2:17-cv-04964?
Answer: Procedural milestones are not provided in the input record.
What milestones matter for business and litigation strategy?
For Hatch-Waxman patent cases, the key events for risk assessment usually include:
- complaint and amendment cadence
- motion to dismiss outcomes
- Markman claim construction schedule and results
- dispositive motion rulings
- final judgment or dismissal
- settlement date and terms summary
- any injunction or licensing provisions
Those facts are not available in the input record.
Did the parties settle, and did SEBELA secure any exclusivity-like relief?
Answer: Settlement or any final adjudication details are not provided in the input record.
What to look for in a settlement for generic entry risk
Business-critical settlement terms normally include:
- launch date commitments (carve-outs and design-around permission)
- covenant not to sue scope
- payment amount (if any) and structure (if any)
- continued exclusivity for certain strengths/forms
- stipulations on invalidity or non-infringement
- post-settlement covenant triggers tied to regulatory approvals
No such terms are present in the provided input.
What is the likely Orange Book and ANDA linkage for 2:17-cv-04964?
Answer: No information is provided about:
- the drug/strength covered
- whether this is a Paragraph IV ANDA suit
- the Orange Book-listed patents involved
- the FDA application number
- whether an injunction was sought
Without product and patent linkage, the regulatory analysis cannot be completed.
How strong is SEBELA’s patent estate versus Prinston’s infringement theory?
Answer: Strength analysis requires at least:
- asserted patent list
- claim construction outcomes
- infringement comparison to Prinston’s product or proposed ANDA
- invalidity arguments and rulings
None of those components are in the input record.
What generic entry risks does 2:17-cv-04964 create for Prinston and other challengers?
Answer: Litigation can affect entry risk through:
- negotiated design-around or carve-out terms
- injunction or dismissal outcomes
- estoppel effect from final judgments
- collateral estoppel in related matters
However, without settlement/judgment facts or asserted patents, risk cannot be quantified for this specific docket.
Key Takeaways
- Case identified: Sebela International Limited v. Prinston Pharmaceutical, Inc. (2:17-cv-04964), filed in 2017.
- Parties identified: Sebela as plaintiff; Prinston as defendant.
- Missing for a complete litigation analysis: asserted patent numbers, claims at issue, procedural timeline, claim construction, dispositive rulings, settlement terms, and final judgment/injunction details are not present in the provided input.
- Business implication: a definitive assessment of generic entry timing, design-around space, and enforceability is not possible without case-specific docket content.
FAQs
-
What patents did Sebela assert against Prinston in 2:17-cv-04964?
Not provided in the input.
-
Was the case resolved via settlement or final judgment?
Not provided in the input.
-
Did the court issue an injunction or consent decree affecting Prinston’s launch?
Not provided in the input.
-
Does 2:17-cv-04964 involve a Paragraph IV ANDA challenge?
Not provided in the input.
-
What is the practical impact of 2:17-cv-04964 on future generic challengers?
Not quantifiable from the provided input due to missing asserted-patent and disposition details.
References
None.
